Anti-Human/Monkey CD40L (CD154) (Clone 5C8) – PE

Human D1.1 T cell line

This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2 – 8° C Wet Ice

Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Clone 5C8 is a mouse monoclonal antibody that targets the human and cynomolgus monkey CD154 (CD40L).

CD154, also known as CD40L, gp39, TRAP, or T BAM is a 39 kDa molecule that plays a vital role in the immune system. It belongs to the tumor necrosis factor (TNF) family and is crucial for the interaction between antigen-specific lymphocytes and antigen-presenting cells^1,2. By binding to CD40 it assists in the costimulation process required for activating T cells and promoting B cell proliferation. CD40L also stimulates the secretion of immunoglobulin and facilitates Ig isotype switching when it binds to CD40 on B-cells³. Moreover, CD40L regulates cytokine production by T cells⁴. Due to its involvement in immune responses, this molecule is of significant importance for immunological research and therapeutic interventions^5,6.

Clone 5C8 is a mouse monoclonal antibody produced through immunization of BALB/c mice with cells from a mouse myeloma cell line. It specifically recognizes human CD154 and binds to an epitope that differs from the CD40 binding site^7,8.

CD154 is primarily expressed on activated T-cells but can also be found in other cell types, including platelets, mast cells, macrophages, basophils, NK cells, B lymphocytes, smooth muscle cells, endothelial cells, and epithelial cells.

CD40

1. Seijkens T, Engel D, Tjwa M, Lutgens E. Thromb Haemost. 104(4):693-701. 2010.
2. Mackey MF, Barth RJ, Noelle RJ. J Leukoc Biol. 63(4):418-428. 1998.
3. Aversa G, Punnonen J, Carballido JM, Cocks BG, De Vries JE. Seminars in Immunology. 6(5):295-301.1994.
4. Armitage RJ, Tough TW, Macduff BM, et al. Eur J Immunol. 23(9):2326-2331.1993.
5. Jabara HH, Brodeur SR, Geha RS. J Clin Invest. 107(3):371-378. 2001.
6. Singh J, Garber E, Van Vlijmen H, et al. Protein Sci. 7(5):1124-1135. 1998.
7. Salvadori B, Cusumano F, Del Bo R, et al. Cancer. 63(12):2532-2536. 1989.
8. Alturaihi H, Hassan GS, Al-Zoobi L, et al. Eur J Immunol. 45(2):592-602. 2015.
9. Nadazdin O, Boskovic S, Wee SL, et al. The Journal of Immunology. 187(9):4589-4597. 2011.
10. Yellin MJ, Brett J, Baum D, et al. J Exp Med. 182(6):1857-1864. 1995.
11. Schnabel CL, Fletemeyer B, Lübke S, Marti E, Wagner B, Alber G. Front Immunol. 13:805026. 2022.
12. Grammer AC, Bergman MC, Miura Y, Fujita K, Davis LS, Lipsky PE. J Immunol. 154(10):4996-5010. 1995.